Related Experiment Video
Updated: Nov 2, 2025

Estimating the Yield of Compounds on the TLC Plate via the Blue-LED Illumination Technique
Published on: October 6, 2022
Stability-indicating UPLC, TLC-densitometric and UV-spectrophotometric methods for alcaftadine determination
Sawsan A Abdel Razeq1, Shimaa E Abdel Aziz1, Nermin S Ahmed2
1Analytical Chemistry Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt.
Abstract:
Three sensitive and precise stability-indicating methods were developed for the determination of alcaftadine in the presence of its degradation products. Efficient separation was achieved using UPLC-UV-MS method by gradient elution with a mobile phase of 0.1% aqueous formic acid (A) and 0.1% formic acid in acetonitrile (B) over concentration range of 0.10-1.00 µg mL-1. The accuracy was 100.89% ± 0.74 and 99.73% ± 0.78 for UV and MS detection, respectively. A TLC-densitometric method was adopted to separate of the intact drug from its degradation products. Methanol: chloroform: glacial acetic acid (5:4:0.1, v/v/v) was the developing system, detection wavelength was set to 282 nm. Rf values were 0.35, 0.65 and 0.88 for alcaftadine, its acidic and oxidative degradants, respectively. The linearity range was 2.00-27.00 µg/band with mean accuracy of 100.58% ± 0.86. The proposed TLC-densitometric method was utilized for the study of degradation rates of alcaftadine. Finally, a simple UV-spectrophotometric method where an induced dual wavelength was implemented, the method showed a linearity range of 2.00-27.00 µg mL-1 with mean recovery of 100.15% ± 0.70. The proposed methods were successful for quantitation of alcaftadine in ophthalmic solution and in plasma samples. The obtained results were in accordance with those obtained by previously reported methods.
More Related Videos
10:22Improved UPLC-UV Method for the Quantification of Vitamin C in Lettuce Varieties Lactuca sativa L. and Crop Wild Relatives Lactuca spp.
Published on: June 30, 2020
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017